Compare AbCellera Biologics Inc (ABCL) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Raymond James Financial, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Raymond James Financial, Inc. trades at $164.94 (market cap $32.66B). The key difference: Raymond James Financial, Inc. is far larger — about 13.9× AbCellera Biologics Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | RJF | |
|---|---|---|
Market Cap | $2.35B | $32.66B |
Sector | Health | Financials |
52-Week High | $8.12 | $176.43 |
52-Week Low | $2.78 | $140.89 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Raymond James Financial (RJF) trades at $167.60, up 3.04% today, near its consensus price target of $168.00. The stock shows a bullish technical trend with strong moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth remains solid, climbing from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. Recent news highlights dividend declarations and record quarterly performance, reinforcing positive sentiment.
Outlook is cautiously optimistic with upside to the high target of $182.00, supported by earnings momentum and analyst coverage. Risks include rising expenses and market volatility. The stock presents a balanced opportunity for growth-oriented investors, though cost management remains a key watchpoint amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
